Hey Anon 2.8 launches with price impact settings and Meteora integration
HeyAnon just dropped version 2.8 of its AI-powered DeFi platform, and the update, which went live on July 30, brings customizable price impact settings, the ability to launch PumpFun pairs denominated in USDC, and single-click zaps into Meteora liquidity positions.
What’s actually in the update
The headline feature is customizable price impact settings. Users can now define acceptable price impact thresholds before executing swaps, giving them granular control over how much market movement they’re willing to absorb on entry or exit.
The 2.8 update also lets users create PumpFun pairs against USDC instead of SOL, which matters for traders who prefer stablecoin-denominated exposure and want to avoid the added variable of SOL price fluctuations.
The Meteora integration allows users to provide liquidity to the protocol’s pools without manually splitting tokens, approving multiple transactions, and navigating Meteora’s own interface. HeyAnon’s conversational AI handles the orchestration, turning what used to be a multi-step process into a single click.
Beyond the marquee features, the release includes eight improvements and three fixes spanning trading functionality, liquidity management, and portfolio tracking.
Why Meteora matters here
Meteora is a Solana-native liquidity protocol with a total value locked of approximately $293 million. It has processed cumulative swap volumes exceeding $340 billion, and fees generated on the platform have surpassed $1.86 billion.
The bigger picture for agentic DeFi
HeyAnon’s platform supports autonomous agents that can execute across both centralized and decentralized finance rails. Its integrations extend beyond Solana, including the Pandora prediction market on Ethereum. The ANON token serves as both the governance mechanism and utility token within this ecosystem.
The price impact settings in 2.8 give users protective guardrails rather than letting the AI run unsupervised, reflecting the tension between abstraction and user control in AI-driven trading interfaces.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly

XRP Ledger adds account control feature, enabling enterprises to manage assets offline.

BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
